Drug Type Small molecule drug |
Synonyms Small Molecules to Antagonize 5HT7 Receptors for Crohn’s Disease and Ulcerative Colitis(PRAEVENTIX), PRA 523, PRA523 |
Target |
Action antagonists |
Mechanism 5-HT7 receptor antagonists(Serotonin 7 (5-HT7) receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pruritus | Preclinical | United States | 01 Apr 2025 | |
| Colitis, Ulcerative | Preclinical | United States | 23 Jul 2019 | |
| Crohn Disease | Preclinical | United States | 23 Jul 2019 |





